Very-early-stage Hepatocellular Carcinoma, Are We at Long Last on Route for Achieving Better Patient Outcomes?
Open Access
- 23 April 2021
- journal article
- editorial
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 000 (000), 000
- https://doi.org/10.14218/jcth.2021.00137
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012Gastroenterology, 2017
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2015
- Comparison of resection and ablation for hepatocellular carcinoma: A cohort study based on a Japanese nationwide surveyJournal of Hepatology, 2012
- Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinomaEmergencias, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Design and Endpoints of Clinical Trials in Hepatocellular CarcinomaJNCI Journal of the National Cancer Institute, 2008
- Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft modelsCancer Chemotherapy and Pharmacology, 2006
- Phase II Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2006
- Early-Stage Hepatocellular Carcinoma in Patients with Cirrhosis: Long-term Results of Percutaneous Image-guided Radiofrequency AblationRadiology, 2005
- Hepatocellular carcinomaThe Lancet, 2003